Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole
A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of re...
Gespeichert in:
Veröffentlicht in: | Pharmaceutical research 1992-03, Vol.9 (3), p.390-397 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 397 |
---|---|
container_issue | 3 |
container_start_page | 390 |
container_title | Pharmaceutical research |
container_volume | 9 |
creator | ELDIN HASSAN, E PARISH, R. C GALLO, J. M |
description | A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations. |
doi_str_mv | 10.1023/A:1015803321609 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73027589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73027589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-46a20ece88319af74b7a655be885a145b09cadc834626fa951362c4d4c5126de3</originalsourceid><addsrcrecordid>eNo9kE1LAzEYhIMotVbPnoQcxJOr-dxsvJXiFxR6UfBW3s1m28husiYpaH-9CxZPAzMPAzMIXVJyRwnj9_MHSqisCOeMlkQfoSmViheaiI9jNCWKiaJSgp6is5Q-CSEV1WKCJrSkQis-Rc1qyK53e9vgNsR-10F2wePQ4h423mZnsNm6HBJ43DsTQxq2NtqETfAZnHd-g_PWYvAjCt7YiGFjfb7F4Xv0IuxDZ8_RSQtdshcHnaH3p8e3xUuxXD2_LubLwrCK5kKUwIg1tqo41dAqUSsopaxHQwIVsibaQGMqLkpWtqAl5SUzohFGUlY2ls_QzV_vEMPXzqa87l0ytuvA27BLa8UJU7LSI3h1AHd1b5v1EF0P8Wd9uGXMrw85JANdG8dlLv1jUkjNFeO_77Jy3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73027589</pqid></control><display><type>article</type><title>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>ELDIN HASSAN, E ; PARISH, R. C ; GALLO, J. M</creator><creatorcontrib>ELDIN HASSAN, E ; PARISH, R. C ; GALLO, J. M</creatorcontrib><description>A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1023/A:1015803321609</identifier><identifier>PMID: 1614973</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Anthraquinones - administration & dosage ; Antineoplastic Agents - administration & dosage ; Biological and medical sciences ; Chitin - analogs & derivatives ; Chitin - chemistry ; Chitosan ; Drug Carriers ; General pharmacology ; Medical sciences ; Microspheres ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Pyrazoles - administration & dosage</subject><ispartof>Pharmaceutical research, 1992-03, Vol.9 (3), p.390-397</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-46a20ece88319af74b7a655be885a145b09cadc834626fa951362c4d4c5126de3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5459372$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1614973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ELDIN HASSAN, E</creatorcontrib><creatorcontrib>PARISH, R. C</creatorcontrib><creatorcontrib>GALLO, J. M</creatorcontrib><title>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.</description><subject>Anthraquinones - administration & dosage</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Chitin - analogs & derivatives</subject><subject>Chitin - chemistry</subject><subject>Chitosan</subject><subject>Drug Carriers</subject><subject>General pharmacology</subject><subject>Medical sciences</subject><subject>Microspheres</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazoles - administration & dosage</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEYhIMotVbPnoQcxJOr-dxsvJXiFxR6UfBW3s1m28husiYpaH-9CxZPAzMPAzMIXVJyRwnj9_MHSqisCOeMlkQfoSmViheaiI9jNCWKiaJSgp6is5Q-CSEV1WKCJrSkQis-Rc1qyK53e9vgNsR-10F2wePQ4h423mZnsNm6HBJ43DsTQxq2NtqETfAZnHd-g_PWYvAjCt7YiGFjfb7F4Xv0IuxDZ8_RSQtdshcHnaH3p8e3xUuxXD2_LubLwrCK5kKUwIg1tqo41dAqUSsopaxHQwIVsibaQGMqLkpWtqAl5SUzohFGUlY2ls_QzV_vEMPXzqa87l0ytuvA27BLa8UJU7LSI3h1AHd1b5v1EF0P8Wd9uGXMrw85JANdG8dlLv1jUkjNFeO_77Jy3g</recordid><startdate>19920301</startdate><enddate>19920301</enddate><creator>ELDIN HASSAN, E</creator><creator>PARISH, R. C</creator><creator>GALLO, J. M</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19920301</creationdate><title>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</title><author>ELDIN HASSAN, E ; PARISH, R. C ; GALLO, J. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-46a20ece88319af74b7a655be885a145b09cadc834626fa951362c4d4c5126de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Anthraquinones - administration & dosage</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Chitin - analogs & derivatives</topic><topic>Chitin - chemistry</topic><topic>Chitosan</topic><topic>Drug Carriers</topic><topic>General pharmacology</topic><topic>Medical sciences</topic><topic>Microspheres</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazoles - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ELDIN HASSAN, E</creatorcontrib><creatorcontrib>PARISH, R. C</creatorcontrib><creatorcontrib>GALLO, J. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ELDIN HASSAN, E</au><au>PARISH, R. C</au><au>GALLO, J. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>1992-03-01</date><risdate>1992</risdate><volume>9</volume><issue>3</issue><spage>390</spage><epage>397</epage><pages>390-397</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>1614973</pmid><doi>10.1023/A:1015803321609</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0724-8741 |
ispartof | Pharmaceutical research, 1992-03, Vol.9 (3), p.390-397 |
issn | 0724-8741 1573-904X |
language | eng |
recordid | cdi_proquest_miscellaneous_73027589 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Anthraquinones - administration & dosage Antineoplastic Agents - administration & dosage Biological and medical sciences Chitin - analogs & derivatives Chitin - chemistry Chitosan Drug Carriers General pharmacology Medical sciences Microspheres Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Pyrazoles - administration & dosage |
title | Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A52%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimized%20formulation%20of%20magnetic%20chitosan%20microspheres%20containing%20the%20anticancer%20agent,%20oxantrazole&rft.jtitle=Pharmaceutical%20research&rft.au=ELDIN%20HASSAN,%20E&rft.date=1992-03-01&rft.volume=9&rft.issue=3&rft.spage=390&rft.epage=397&rft.pages=390-397&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1023/A:1015803321609&rft_dat=%3Cproquest_pubme%3E73027589%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73027589&rft_id=info:pmid/1614973&rfr_iscdi=true |